Veeva Systems (NYSE:VEEV) Updates FY 2027 Earnings Guidance

Veeva Systems (NYSE:VEEV) issued an update on its FY 2027 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 9.210-9.210 for the period, compared to the consensus EPS estimate of 8.580. The company issued revenue guidance of $3.7 billion-$3.7 billion, compared to the consensus revenue estimate of $3.6 billion. Veeva Systems also updated its Q3 2027 guidance to 2.330-2.340 EPS.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on VEEV. Zacks Research lowered Veeva Systems from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. BNP Paribas Exane reissued an “outperform” rating and issued a $285.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Guggenheim raised their price target on Veeva Systems from $232.00 to $276.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. The Goldman Sachs Group decreased their price objective on shares of Veeva Systems from $190.00 to $165.00 and set a “sell” rating on the stock in a research report on Thursday, June 4th. Finally, Weiss Ratings raised shares of Veeva Systems from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, August 12th. Nineteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $258.08.

Veeva Systems Price Performance

Shares of VEEV traded down $2.06 on Wednesday, reaching $244.72. The company’s stock had a trading volume of 1,400,990 shares, compared to its average volume of 2,452,867. The stock’s 50 day simple moving average is $201.60 and its two-hundred day simple moving average is $182.61. Veeva Systems has a 12-month low of $148.05 and a 12-month high of $310.50. The stock has a market capitalization of $39.75 billion, a P/E ratio of 43.62, a PEG ratio of 1.07 and a beta of 0.92.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings data on Wednesday, August 26th. The technology company reported $1.68 earnings per share for the quarter, missing analysts’ consensus estimates of $2.22 by ($0.54). Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Analysts expect that Veeva Systems will post 6.64 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Thomas D. Schwenger sold 36,000 shares of Veeva Systems stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the sale, the insider owned 19,449 shares in the company, valued at $4,866,723.27. This trade represents a 64.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is owned by insiders.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Major customer wins strengthen Vault CRM adoption. Biogen and Regeneron both committed to Veeva Vault CRM globally. The agreements support Veeva’s position in life-sciences commercial software and could contribute to future subscription growth. Veeva Vault CRM Selected by Biogen Veeva Vault CRM Selected by Regeneron
• Positive Sentiment: Truist said the wins reinforce Veeva’s market leadership. The bank characterized Vault CRM as the clear leader in life-sciences CRM ahead of earnings, providing a favorable read-through on competitive positioning and demand. Veeva’s Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings
• Positive Sentiment: Needham reaffirmed its “Buy” rating. The repeated bullish recommendation adds support to the investment case as investors assess Veeva’s growth prospects and valuation. Needham Reaffirms Buy Rating
• Neutral Sentiment: Piper Sandler initiated coverage. New analyst coverage may increase institutional attention, although the article does not specify the firm’s rating or price target. Veeva Coverage Initiated at Piper Sandler
• Neutral Sentiment: Earnings remain the near-term catalyst. Veeva is scheduled to report second-quarter results after the bell. Its previous quarter exceeded consensus estimates, with revenue up 16.3% year over year, so investors will focus on results, subscription growth, and forward guidance. What to Expect From Veeva Systems’s Q2 Earnings

Institutional Investors Weigh In On Veeva Systems

Several institutional investors have recently made changes to their positions in the company. Durable Capital Partners LP bought a new stake in Veeva Systems during the 2nd quarter valued at about $281,351,000. AQR Capital Management LLC raised its position in shares of Veeva Systems by 31.2% in the 3rd quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company’s stock worth $706,078,000 after acquiring an additional 574,164 shares in the last quarter. Greenoaks Capital Partners LLC boosted its holdings in shares of Veeva Systems by 198.2% in the 4th quarter. Greenoaks Capital Partners LLC now owns 694,926 shares of the technology company’s stock valued at $155,128,000 after buying an additional 461,908 shares in the last quarter. Federated Hermes Inc. grew its holdings in Veeva Systems by 50.4% in the fourth quarter. Federated Hermes Inc. now owns 1,030,312 shares of the technology company’s stock worth $229,997,000 after purchasing an additional 345,051 shares during the last quarter. Finally, Amundi increased its position in shares of Veeva Systems by 48.6% during the fourth quarter. Amundi now owns 919,467 shares of the technology company’s stock worth $205,253,000 after purchasing an additional 300,720 shares in the last quarter. Institutional investors own 88.20% of the company’s stock.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.